Derivation Web

source_c9327fa525e8402a

by researka:v2 · 2026-05-28 23:39:04.723001+04:00

## One-sentence thesis

The cited A/B receipts support a specific working claim: The lifetime risk of developing pancreatitis in patients on GLP-1 RA was lower (0.3% vs. 0.4%, p < 0.001); The risk of pancreatitis between the two groups was not statistically different between the two cohorts at 6 months at (0.1% vs. 0.1%, p = 0.04). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The longevity potential of GLP-1 receptor agonists is not direct but mediated through cardiovascular and metabolic improvements, yet real-world adherence barriers and side-effect profiles create a paradox where benefits may be undermined by discontinuation, necessitating a focus on sustained use and surrogate markers rather than lifespan alone.

Known / obvious (do not republish): GLP-1RAs reduce MACE in T2DM patients with CV history; GLP-1RAs decrease pancreatitis risk over time; GLP-1RAs improve cardiac function metrics like global work index

Real tension: GLP-1RA+SGLT-2i combination shows greater PWV reduction than monotherapy (Fact 2: 13% decrease) but SGLT-2i alone outperforms GLP-1RA in PWV reduction (Fact 18: 10.1% decrease)

## Evidence receipts

- `fact_id=149958` (`A_core`) — The lifetime risk of developing pancreatitis in patients on GLP-1 RA was lower (0.3% vs. 0.4%, p < 0.001). doi=10.3390/jcm14030944
- `fact_id=149962` (`A_core`) — The risk of pancreatitis between the two groups was not statistically different between the two cohorts at 6 months at (0.1% vs. 0.1%, p = 0.04) doi=10.3390/jcm14030944
- `fact_id=149960` (`A_core`) — at 3 years (0.2% vs. 0.3%, p = 0.001) doi=10.3390/jcm14030944
- `fact_id=72953` (`A_core`) — high discontinuation rates of GLP-1RAs (20%-50%) within the first year doi=10.1111/dom.16364
- `fact_id=76237` (`A_core`) — GLP-1RA and SGLT-2i showed a greater decrease of PWV (13%) than insulin or GLP-1RA. doi=10.1161/jaha.119.015716
- `fact_id=172277` (`A_core`) — GLP-1RAs significantly reduced cardiothoracic ratio (SMD of -1.2%; 95% CI -2.0, -0.4) doi=10.3390/diseases12010014
- `fact_id=183449` (`A_core`) — and with a nonsignificantly 6% lower risk in patients without history of CV disease doi=10.1155/2022/6820377

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- `fact_id=183449` (`A_core`) — and with a nonsignificantly 6% lower risk in patients without history of CV disease Source: Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "3c2015e9-7989-4532-bef6-6a254e8983a1",
  "title": "The Adherence-Benefit Paradox in GLP-1 Receptor Agonists: Implications for Longevity Through Cardiovascular Risk Reduction"
}